Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R de Wit

Showing results (61-70 of 147) with videos related to

Pageof 15
Sort By:
British Journal of Cancer|November 17, 2001
Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapyR de Wit, A C de Boer, G H vd Linden, et al.
Journal of the National Cancer Institute|October 2, 1996
Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor supportR de Wit, J Verweij, M Bontenbal, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 1, 1990
Palliative radiation therapy for AIDS-associated Kaposi's sarcoma by using a single fraction of 800 cGyR de Wit, W G Smit, K H Veenhof, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1995
The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancerP Deprés-Brummer, M Itzhaki, P J Bakker, et al.
British Journal of Cancer|July 1, 1996
Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tabletsR de Wit, J H Beijnen, O van Tellingen, et al.
Breast Cancer Research and Treatment|May 23, 2001
Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxaneC H Smorenburg, M Bontenbal, C Seynaeve, et al.
Breast Cancer Research and Treatment|May 1, 1995
Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancerM Bontenbal, A S Planting, J Verweij, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1994
Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapyR de Wit, M E van der Burg, A van den Gaast, et al.
Lancet (London, England)|November 26, 1988
Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcomaR de Wit, J K Schattenkerk, C A Boucher, et al.
Environmental Microbiology|February 28, 2001
Sulphate reduction and nitrogen fixation rates associated with roots, rhizomes and sediments from Zostera noltii and Spartina maritima meadowsL B Nielsen, K Finster, D T Welsh, et al.
Pageof 15

Showing results (61-70 of 147) with videos related to

Sort By:
Pageof 15
British Journal of Cancer|November 17, 2001
Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapyR de Wit, A C de Boer, G H vd Linden, et al.
Journal of the National Cancer Institute|October 2, 1996
Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor supportR de Wit, J Verweij, M Bontenbal, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 1, 1990
Palliative radiation therapy for AIDS-associated Kaposi's sarcoma by using a single fraction of 800 cGyR de Wit, W G Smit, K H Veenhof, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1995
The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancerP Deprés-Brummer, M Itzhaki, P J Bakker, et al.
British Journal of Cancer|July 1, 1996
Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tabletsR de Wit, J H Beijnen, O van Tellingen, et al.
Breast Cancer Research and Treatment|May 23, 2001
Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxaneC H Smorenburg, M Bontenbal, C Seynaeve, et al.
Breast Cancer Research and Treatment|May 1, 1995
Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancerM Bontenbal, A S Planting, J Verweij, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1994
Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapyR de Wit, M E van der Burg, A van den Gaast, et al.
Lancet (London, England)|November 26, 1988
Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcomaR de Wit, J K Schattenkerk, C A Boucher, et al.
Environmental Microbiology|February 28, 2001
Sulphate reduction and nitrogen fixation rates associated with roots, rhizomes and sediments from Zostera noltii and Spartina maritima meadowsL B Nielsen, K Finster, D T Welsh, et al.
Pageof 15